Academic literature on the topic 'Febrilna neutropenija'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Febrilna neutropenija.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Febrilna neutropenija"
1
Pichereau, Solen, Anne Le Louarn, Thierry Lecomte, Hélène Blasco, Chantal Le Guellec, and Hélène Bourgoin. "Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer." Journal of Pharmacy & Pharmaceutical Sciences 13, no. 4 (January 3, 2011): 615. http://dx.doi.org/10.18433/j3wk5s.
Full textAbstract:
PURPOSE: Functional polymorphisms of the UGT1A1 gene, particularly the UGT1A1*28 variant, are associated with the severity of the bone marrow suppression in patients with metastatic colorectal cancer receiving irinotecan. This study assesses the cost-effectiveness of screening for UGT1A1*28 polymorphism associated with primary prophylactic Granulocytes Colony Stimulating Factor in patients homozygous for the *28 allele. The effectiveness was estimated based on the number of neutropenia avoided. METHODS: We modelled a theoretical population treated with combined 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for metastatic colorectal cancer. A decision tree simulated the health outcomes, measured by the prevalence of neutropenic events for two strategies, with or without UGT1A1 genotype screening. The model incorporated direct hospital costs and was validated with a sensitivity analysis. We calculated the cost-effectiveness ratio: CE=∆C / ∆E = "genotyping" cost – "no genotyping" cost / number of febrile neutropenia avoided. RESULTS: In the "genotyping strategy", the cost to avoid one febrile neutropenia event per 1000 patients treated was € 942.8 to € 1090.1. The sensitivity analysis showed a better CE ratio of € 733.4 to € 726.6 per febrile neutropenic event avoided.CONCLUSIONS: UGT1A1 genotype screening before irinotecan treatment is a cost-efficient strategy for the hospital. Systematic genotyping prior to chemotherapy, and administration of CSF in patients homozygotes for the *28 allele allow to avoid 91 febrile neutropenias at an acceptable cost.
2
Sugahara, Hiroyuki, Masao Mizuki, Sayoko Matsumae, Yoshiko Nabetani, Motoko Kikuchi, and Yuzuru Kanakura. "Footwear Exchange Has No Influence on the Incidence of Febrile Neutropenia in Patients Undergoing Chemotherapy for Hematologic Malignancies." Infection Control & Hospital Epidemiology 25, no. 1 (January 2004): 51–54. http://dx.doi.org/10.1086/502292.
Full textAbstract:
AbstractObjective:To determine whether footwear exchange affects the incidence of febrile neutropenia among patients undergoing chemotherapy for hematologic malignancies.Design:Open trial with historical comparison.Setting:The 12-bed high-efficiency particulate air-fil-tered hematology unit at Osaka University Hospital, Suita, Japan.Patients:Those with hematologic malignancies who underwent chemotherapy from January 1997 through January 2003. Footwear exchange was discontinued in January 2000.Methods:The surveillance system was based on the National Nosocomial Infections Surveillance System of the Centers for Disease Control and Prevention. Rates of febrile neutropenia were calculated for neutropenic patient-days (ie, days with neutropenia < 500/μL).Results:From January 1997 through December 1999 and from February 2000 through January 2003, 58 and 54 patients endured 237 and 184 neutropenic periods following chemotherapy, and their total neutropenic days were 3,123 and 2,503, respectively. They showed episodes of febrile neutropenia 89 and 68 times, respectively. Infection rates were 28.5 and 27.2 per 1,000 neutropenic patient-days (P = .83), respectively.Conclusion:The incidence of febrile neutropenia was not affected by footwear exchange. In hematology units, changing shoes does not appear to affect the rate of infections during neutropenic periods.
3
Strojnik, Ksenija, Ksenija Mahkovic-Hergouth, Barbara Jezersek Novakovic, and Bostjan Seruga. "Outcome of severe infections in afebrile neutropenic cancer patients." Radiology and Oncology 50, no. 4 (December 1, 2016): 442–48. http://dx.doi.org/10.1515/raon-2016-0011.
Full textAbstract:
Abstract Background In some neutropenic cancer patients fever may be absent despite microbiologically and/or clinically confirmed infection. We hypothesized that afebrile neutropenic cancer patients with severe infections have worse outcome as compared to cancer patients with febrile neutropenia. Patients and methods We retrospectively analyzed all adult cancer patients with chemotherapy-induced neutropenia and severe infection, who were admitted to the Intensive Care Unit at our cancer center between 2000 and 2011. The outcome of interest was 30-day in-hospital mortality rate. Association between the febrile status and in-hospital mortality rate was evaluated by the Fisher’s exact test. Results We identified 69 episodes of severe neutropenic infections in 65 cancer patients. Among these, 9 (13%) episodes were afebrile. Patients with afebrile neutropenic infection presented with hypotension, severe fatigue with inappetence, shaking chills, altered mental state or cough and all of them eventually deteriorated to severe sepsis or septic shock. Overall 30-day in-hospital mortality rate was 55.1%. Patients with afebrile neutropenic infection had a trend for a higher 30-day in-hospital mortality rate as compared to patients with febrile neutropenic infection (78% vs. 52%, p = 0.17). Conclusions Afebrile cancer patients with chemotherapy-induced neutropenia and severe infections might have worse outcome as compared to cancer patients with febrile neutropenia. Patients should be informed that severe neutropenic infection without fever can occasionally occur during cancer treatment with chemotherapy.
4
Lee, Pauline, Randall W. Knoebel, Jennifer Pisano, and Natasha N. Pettit. "Moxifloxacin versus levofloxacin for antibacterial prophylaxis in acute leukemia patients." Journal of Oncology Pharmacy Practice 25, no. 3 (January 8, 2018): 758–61. http://dx.doi.org/10.1177/1078155217752074.
Full textAbstract:
Objective The primary endpoint of this study was to determine the incidence of febrile neutropenia among patients receiving either moxifloxacin or levofloxacin for antibacterial prophylaxis. Secondary endpoints were number of documented infections and in-hospital mortality in patients who develop febrile neutropenia. Methods A single-center retrospective cohort analysis at a large tertiary care academic medical center was conducted. This study included adult acute leukemia patients (age ≥18 years old) who received inpatient antibacterial prophylaxis (moxifloxacin or levofloxacin) from 1 July 2012 to 1 October 2014. Patients were excluded from the study if they were treated with antimicrobial therapy in the preceding five days or admitted to the hospital with neutropenic fever. Fisher’s exact test was used for categorical data and Mann–Whitney test for continuous data. Logistic regression analysis was used to determine risk factors for febrile neutropenia. Results Eighty-five patients were included in the final analysis with 40 patients who received moxifloxacin and 45 patients who received levofloxacin. Baseline characteristics were similar between the two groups. Twenty-two patients experienced febrile neutropenia requiring intravenous antibiotics in the moxifloxacin group and 30 patients in the levofloxacin group (P = 0.190). Age and duration of neutropenia appeared to predict for febrile neutropenia; however, after multivariate analysis, longer duration of neutropenia was shown to be the best predictor for febrile neutropenia with an odds ratio of 4.69 (95% CI, 1.697–12.968). Both groups had similar rates of documented infections and in-hospital morality. Conclusion Moxifloxacin and levofloxacin showed similar rates of febrile neutropenia when used for neutropenic antibacterial prophylaxis in acute leukemia patients.
5
Nyatsanza, Ignatius, Irum Khan, Jennifer Windhorst, Nicole Gerardo, Kasandra Cadman, LeeAnn Valero, Eileen Knightly, Lawrence Eric Feldman, William Galanter, and Neeta K. Venepalli. "Timely antibiotic administration in febrile neutropenia." Journal of Clinical Oncology 35, no. 8_suppl (March 10, 2017): 204. http://dx.doi.org/10.1200/jco.2017.35.8_suppl.204.
Full textAbstract:
204 Background: The University of Illinois currently lacks a standard process to ensure timely antibiotic administration for patients with febrile neutropenia. The Infectious disease society of America (IDSA) guidelines recommend administration of antibiotics within two hours. Given the variability in patient encounters, we sought to implement an early identification and interventional strategy in the ambulatory setting for febrile neutropenic patients. A retrospective chart review over 10 weeks demonstrated that of 40 patients diagnosed with neutropenia 15 % (N = 6) had febrile neutropenia. Of these 6 patients, 50% (N = 3) received antibiotics within the IDSA time frame. We aimed to increase the percentage of febrile neutropenic patients receiving antibiotics within 2 hours from 50% to 100% in 8 weeks. Methods: A focus group at our quarterly morbidity mortality and improvement conference brainstormed a list of causes of delay in antibiotic initiation based on an index case discussion. A task force generated a pareto chart after affinity sorting the prior list, and created actual and ideal process maps, from identification of neutropenic patients to patient disposition. A standard operative protocol (SOP) was developed involving the creation and implementation of an electronic provider generated neutropenia check list triggering specific actions per IDSA recommendations, and a standardized order set including STAT cultures, and STAT antibiotics. Results: The febrile neutropenia SOP will be piloted over an 8 week period starting in early November in four ambulatory settings. The primary outcome data is the time from event to antibiotic administration. Process data will include time from event to antibiotic order, time from antibiotic order to administration and compliance with high risk neutropenic check list. We plan to assess our interventions every 3-4 weeks, and pilot at least 2 PDSA cycles within the next 8 weeks. Conclusions: Although febrile neutropenia is a recognized medical emergency with clear guidelines on treatment, not all patients may receive antibiotics within the appropriate time frame. It is therefore imperative for institutions to be aware of their level of IDSA compliance and implement appropriate quality improvements as required.
6
Raufi, Ali Mehmood, Shada Attraplsi, and Yehuda Z. Lebowicz. "Better utilization of neutropenic precautions and adherence to guidelines to improve cost effectiveness and patient convenience." Journal of Clinical Oncology 34, no. 7_suppl (March 1, 2016): 227. http://dx.doi.org/10.1200/jco.2016.34.7_suppl.227.
Full textAbstract:
227 Background: Cancer patient are generally immunocompromised and are at increased risk of infections once absolute neutrophils count is less than 500. The aim of the study to evaluate the inpatient utilization of a standardized neutropenic precautions in cancer patients admitted with febrile neutropenia. Methods: From Jan 2010 to May 2015, established cancer patients were included in this retrospective study who were admitted in Cabel Huntington hospital, Huntington, WV with a diagnosis of febrile neutropenia and were placed on Neutropenic precautions (NP). We analyzed if NP were discontinued once patient is stable and no longer neutropenic during hospital stay. Results: A total of 159 cancer patients with admitting diagnosis of febrile neutropenia were identified. 107 out of 159 (67%) patients had solid malignancies while 33% had hematologic malignancies. Median age was 61 (Range of 20-88 years). 69 patients were male while 90 patients were female. Median duration of Neutropenic precautions (NP) was 4 (Mean 5.69 and range: 1-35). NP were appropriately discontinued in 30% of patients during hospital stay however approximately 70% of patients continued to be on NP even after neutropenia resolved (48 vs 111 patients). Median duration of unnecessary NP was 3 with a mean of 3.87 and range of 1-18 days. Conclusions: Better utilization of Neutropenic precautions and adherence to guidelines will improve overall cost effectiveness as well as patient convenience by avoiding unnecessary restriction.
7
Da Silva, Thamires Branco, Guilherme Rossi Assis de Mendonça, Maiara Marx Luz Fiusa, Brunna Eulalio Alves, Rodolfo Monteiro Enz Hubert, Melina Veiga Rodrigues, Vanessa Miho Tani, Jose Vassallo, Fabio Rogério, and Erich Vinicius De Paula. "Sepsis in Patients with Febrile Neutropenia: A Clinical and Autopsy-Based Study." Blood 126, no. 23 (December 3, 2015): 4622. http://dx.doi.org/10.1182/blood.v126.23.4622.4622.
Full textAbstract:
Abstract Introduction: Sepsis in febrile neutropenia (FN) is a life threatening condition, and a health problem of increasing proportions. Although multiple organ dysfunction syndrome (MODS) frequently precedes death in patients with sepsis, the ultimate mechanisms responsible for organ dysfunction and tissue damage in sepsis are yet to be determined. Currently, tissue damage is attributed to an exacerbated response of the immune and hemostatic systems, mediated by endothelial cells, platelets and neutrophils. Of note, recent evidence demonstrated that neutrophils, platelets and fibrin participate in this response by mediating neutrophil extracellular traps (NET) formation, and promoting the hemostatic containment of infectious foci. In animal models, down-regulation of NET formation, coagulation and platelet activation are usually associated with deficiencies in pathogen clearance. Unfortunately, activation of hemostasis and NET formation could potentially contribute to tissue damage by a process called "immunethrombosis". Although the increase of sepsis severity in patients with severe neutropenia is well described, the mechanisms of sepsis-associated tissue damage in the context of severe neutropenia/thrombocytopenia are yet to be determined. Methods: In order to investigate the mechanisms of tissue damage in the context of severe neutropenia/thrombocytopenia, we compiled clinical data from two different prospective sepsis cohorts (A, neutropenic; n=129; and B, non-neutropenic; n=30) followed at our Institution. In addition, we reviewed histopathological data from 16 autopsies of individuals with hematological malignancies and septic shock from our institution (cohort C; n=16). H&E-stained slides from liver, kidneys and lungs were systematically analyzed by one investigator, and reviewed by 2 experienced pathologists, all of them blind to the presence or absence of neutropenia and thrombocytopenia. In each organ, we characterized (as present or absent) three main organic lesions: thrombi in microvessels, microorganism colonies, and inflammatory infiltrate (mononuclear and polymorphonuclear). Inflammation was graded as weak or intense, and only considered when there was no neoplastic infiltration. Results: Median ages of patients from cohorts A and B were respectively 46.0 years (13-78), and 59.4 years (22-85); P<0.0001. In cohort A, neutrophil counts were < 100/mcl in 55.8% of patients and between 100-500/mcl in 42.6%. Platelet counts were also lower in cohort A (30,126 vs 213,933/mcl; P<0.0001). Median SOFA scores (at admission) were 4 (0-15) and 5 (0-17); P=0.3 in neutropenic and non-neutropenic patients respectively, and sepsis-related mortality was 22.5% and 10.3% in the same groups (P=0.19). Among patients with a higher SOFA score, mortality was higher in neutropenic patients (100% vs 33.3%; p=0.04). The frequencies of clinically-evident infection foci were 60% in cohort A and 100% in cohort B (P=0.0001). In contrast, positive blood cultures were present in 38% of neutropenic, but in only 3.3% of non-neutropenic patients (P<0.0001). The autopsy-based study included 10 patients with lymphoma and 6 with acute leukemia. The cause of death was septic shock in all of them, and three patients presented severe neutropenia (<500/mcl). The main histological findings are shown in table 1. The only neutropenic patient with microthrombi presented AML-M3 and leukostasis. Using H&E staining, no bacterial colonies were found in any slide. Conclusions: as expected, septic patients with severe neutropenia presented a worse outcome compared to non-neutropenic patients in our cohort. In addition, the lower frequency of clinically-defined infectious foci, coupled with a strikingly higher frequency of positive blood cultures, suggest that severe neutropenia and thrombocytopenia could impair pathogen containment and clearance. Severe neutropenia/thrombocytopenia was compatible with inflammatory infiltrates and microvascular thrombosis in lungs, although the latter was only observed in a patient with leukostasis and promyelocityc acute leukemia. Table 1. Histological findings in autopsies of neutropenic and non-neutropenic patients Microthrombi Inflammation (weak/intense) Lungs Kidney Liver Lungs Kidney Liver Neutropenic 33% 33% 0% 50%/50% 0%/0% 0%/0% Non-neutropenic 56.25% 25% 6.25% 70%/20% 34%/9% 67%/0% Disclosures No relevant conflicts of interest to declare.
8
Demirel, Aslıhan, Fehmi Tabak, M. Cem Ar, Bilgül Mete, Şeniz Öngören, Mücahit Yemişen, Reşat Özaras, et al. "Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode." Turkish Journal of Hematology 32, no. 3 (September 5, 2015): 243–50. http://dx.doi.org/10.4274/tjh.2013.0422.
Full text
9
Rattanathammethee, Thanawat, Pokpong Piriyakhuntorn, Sasinee Hantrakool, Chatree Chai-Adisaksopha, Ekarat Rattarittamrong, Adisak Tantiworawit, Lalita Norasetthada, et al. "Gut Microbiota Profiles of Treatment-Naïve Adult Acute Myeloid Leukemia Patientswith Neutropenic Fever during Intensive Chemotherapy." Blood 136, Supplement 1 (November 5, 2020): 38–39. http://dx.doi.org/10.1182/blood-2020-140936.
Full textAbstract:
Background : The intestinal bacterial flora of febrile neutropenic patients has been found to be significantly diverse and may play a role in clinical decisions regarding antimicrobial de-escalation with predictive complications. However, there are few reports of microbiota alteration of adult acute myeloid leukemia (AML) patients. Methods : Stool samples of each treatment-naïve AML patient were collected the day before the initiation of induction chemotherapy (pretreatment), on the first date of neutropenic fever and first date of bone marrow recovery. Bacterial DNA was extracted from stool samples and bacterial 16s ribosomal RNA genes were sequenced by next-generation sequencing. Relative abundance, overall richness, Shannon's diversity index and Simpson's diversity index were calculated. Results : Ten AML patients (4 men and 6 women) were included with a median age of 39 years (range: 19-49). Twenty-four stool samples were collected and assigned into three groups: (1) pretreatment (n = 10); (2) first date of febrile neutropenia (n=9); and (3) first date of bone marrow recovery (n=5). All of patients developed febrile neutropenia; three patients had detectable infectious organisms and all of these cases had invasive pulmonary aspergillosis with two being co-infected with Pseudomonas pneumonia and Escherichia coli septicemia. Median absolute neutrophil count was 2.85 x 109/L (range: 1.42-7.67 x 109/L), 0.04 x 109/L (range: 0.01-0.43 x 109/L) and 3.65 x 109/L (range: 2.09-5.78 x 109/L) at pretreatment, first date of febrile neutropenia and first date of bone marrow recovery, respectively. At the phylum level, Firmicutes dominated over the period of neutropenic fever, subsequently declining after bone marrow recovery a pattern in contrast to that shown by Bacteroidetes and Proteobacteria. At the genus level, Enterococcus was more abundant in the febrile neutropenia period compared to pretreatment (mean difference of 20.2, [95%CI (5.9, 34.6)]; P <0.01) whileBacteroides and Escherichia notably declined during the same period (mean difference of -11.7, [95%CI (-21.9, -1.4)]; P= 0.027 and -11.6, [95%CI (-22.7, -0.4)]; P = 0.034, respectively). At the operational taxonomic units (OTUs) level, there was a significantly higher level of overall richness in the pretreatment period than in the febrile neutropenic episode (mean OTUs of 203.1 vs. 131.7; P = 0.012). Both of the diversity indexes of Shannon and Simpson showed a significant decrease in the febrile neutropenic period. Conclusions : Adult AML patients with a first episode of febrile neutropenia after initial intensive chemotherapy demonstrated a significant decrease in gut microbiota diversity and the level of diversity remained constant despite recovery of bone marrow. Figure Disclosures No relevant conflicts of interest to declare.
10
Martinez Lago, Nieves, Maria Vieito, Urbano Anido, Sonia Candamio, Rafael Lopez, Francisco J. Barón, Yolanda Vidal, et al. "Retrospective study of febrile neutropenia." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e19505-e19505. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19505.
Full textAbstract:
e19505 Background: Although its mortality has decreased in the last years, neutropenic fever is still one of the most important oncological emergencies. Methods: We have assessed the epidemiological data on patients admitted or evaluated for neutropenic sepsis in a third level cancer center from January 2009 to December 2010. Results: We have found 68 patients who had at least one episode of febrile neutropenia, of them 66% were male and 34% female, and the mean age was 59 years. The performance status was 0 and 1 in 80% of patients and only 19% percent had serious comorbilities such as renal dysfunction, cirrhosis, diabetes mellitus or chronic pulmonary disease. 36% of our patients had a high risk neutropenic fever per MASCC criteria. The majority of patients were lung cancer (31%) breast cancer (22%); and gastrointestinal cancer (28%) and 53% where treated with palliative intention. The episodes of febrile neutropenia were more frequent in patients in first line of treatment (72%) and first cycle of any treatment (42%). 8% of patients were treated with chemorradiation and 35% of the patients were receiving prophylaxis with GCSF. There was no found the source of the infection in 45% of patients. 25% had positive cultures. The porcetaje of infections with gram-positive and-negative was very similar. Patients were treated with a combination of amikacine and ceftacidime in 63% of times, further addition of vancomicine or antifungical therapies were only needed in minority of patients, 88% percent of patients received granulocyte stimulating factors. The mean duration of the neutropenia was of 2 days. Following chemotherapy treatment doses were reduced in 44% of patients and delayed in 26%. Thirteen percent of patients received secondary prophylaxis with GCSF, treatment regimen changed was changed in only 2% of patients and 29% received no further treatment. Conclusions: The mortality rate was of 3%, and the time of hospitalization was short (mean of 7 days). Febrile neutropenia remains a serious complication that we have to decrease.
Dissertations / Theses on the topic "Febrilna neutropenija"
1
Ivanka, Perčić. "Serumski adiponektin i insulinska rezistencija u febrilnoj neutropeniji kod bolesnika sa akutnom nelimfoblastnom leukemijom." Phd thesis, Univerzitet u Novom Sadu, Medicinski fakultet u Novom Sadu, 2015. https://www.cris.uns.ac.rs/record.jsf?recordId=95376&source=NDLTD&language=en.
Full textAbstract:
Uvod: Febrilna neutropenija, kao prvi znak infekcije, je česta komplikacija u fazi postterapijske aplazije kostne srži u obolelih od akutne nelimfoblastne leukemije. Klinička slika febrilne neutropenije može biti suptilna, a progresija u stanje septičnog šoka znatno brža nego kod imunokompetentnih bolesnika. Rana predikcija rizika od komplikacija febrilne neutropenije i uvođenje empirijske antibiotske terapije može da poboljša prognozu bolesnika. Insulinska rezistencija, dislipidemija i inflamacija masnog tkiva se javljaju u sklopu sistemske inflamacije. Njihova uloga i značaj kao potencijalnih faktora predikcije toka i ishoda febrilne neutropenije nisu ispitani. Ciljevi istraživanja: Ustanoviti promene pokazatelja stepena insulinske senzitivnosti, ukupnog holesterola, triglicerida, HDL - holesterola, LDL - holesterola, apolipoproteina A-I, lipoproteina (a) i adiponektina pre i u fazi febrilne neutropenije kod bolesnika sa akutnom nelimfoblastnom leukemijom. Uporediti vrednosti pokazatelja stepena insulinske senzitivnosti, ukupnog holesterola, triglicerida, HDL - holesterola, LDL - holesterola, apolipoproteina A-I, lipoproteina (a) i adiponektina bolesnika sa akutnom nelimfoblastnom leukemijom pre početka febrilne neutropenije i kontrolne grupe gojaznih. Uporediti vrednosti pokazatelja stepena insulinske senzitivnosti, ukupnog holesterola, triglicerida, HDL - holesterola, LDL - holesterola, apolipoproteina A-I, lipoproteina (a) i adiponektina bolesnika sa akutnom nelimfoblastnom leukemijom u fazi febrilne neutropenije i kontrolne grupe gojaznih. Utvrditi da li su pokazatelj stepena insulinske senzitivnosti, ukupni serumski holesterol, trigliceridi, HDL - holesterol, LDL - holesterol, apolipoprotein A-I, lipoprotein (a) i adiponektin bolesnika sa akutnom nelimfoblastnom leukemijom u fazi febrilne neutropenije u korelaciji sa vrednostima parametara inflamacije, njenim tokom i ishodom. Materijal i metode: Istraživanje je sprovedeno u Klinici za hematologiju i Klinici za endokrinologiju, dijabetes i bolesti metabolizma. Obuhvatilo je 60 ispitanika, od kojih je 30 ispitanika obolelo od akutne nelimfoblastne leukemije, a 30 ispitanika je činilo kontrolnu grupu gojaznih. Nakon uključivanja u istraživanje, ispitanicima su urađeni predviđeni pregledi i laboratorijske analize u cilju procene insulinske senzitivnosti, metaboličkog statusa i serumskog adiponektina. Navedena merenja su urađena pre hemioterapije i u febrilnoj neutropeniji. Zdravstveno stanje ispitanika je praćeno do kraja prve hospitalizacije. Statistička obrada je izvršena uz pomoć statističkog paketa Statistica. Podaci su predstavljeni tabelarno i grafički, a statistička značajnost je odreĎivana na nivou p < 0.05. Rezultati: U febrilnoj neutropeniji bolesnika sa akutnom leukemijom je došlo do razvoja insulinske rezistencije (t = - 2.43, p = 0.021), dislipidemije sa značajnim sniţenjem ukupnog holesterola (t = 3.59, p = 0.0012), LDL – holesterola (t = 3.56, p = 0.0013) i apoA – I (t = 2.27, p = 0.03). Oboleli od akutne nelimfoblastne leukemije u febrilnoj neutropeniji su razvili metaboličke promene viđene kod gojaznih osoba sa insulinskom rezistencijom. Nastanak i progresija insulinske rezistencije je bila u pozitivnoj korelaciji sa fibrinogenom kao pokazateljem težine inflamacije (r = 0.59, p < 0.05) dok je apoA - I negativno korelirao sa CRP (r = - 0.37, p < 0.05). Ispitanici sa nižom insulinemijom i vrednostima HDL - holesterola pre hemoterapije su imali značajno bolji tok febrilne neutropenije (t = -2.38, p = 0.024 vs. t = - 2.87, p = 0.007). Ispitanici sa većim indeksom telesne mase (BMI) i obimom struka imali su povoljniji ishod febrilne neutropenije (r = - 0.47, p < 0.05 vs. r = - 0.40, p < 0.05). Drugi pokazatelji insulinske senzitivnosti, metaboličkog statusa i adiponektin nisu značajno uticali na tok i ishod febrilne neutropenije. Normalna telesna masa pre hemioterapije, a u febrilnoj neutropeniji temperatura u trajanju dužem od 7 dana, niže vrednosti MASCC indeksa rizika, više vrednosti CRP, više vrednosti adiponektina, niže vrednosti Lp(a) i komplikovan tok febrilne neutropenije su bili prediktori lošije prognoze febrilne neutropenije. Zaključak: Pored klasičnih hematoloških parametara potrebno je uzeti u obzir antropometrijske karakteristike, redistribuciju masne mase, disfunkcionalnost masne mase, insulinsku rezistenciju i metaboličke parametre u cilju praćenja i predviđanja mogućih komplikacija i komorbiditeta.Introduction: Febrile neutropenia is a common complication in posttreatment aplasia in patients with acute nonlymphoblastic leukemia. Its clinical manifestation can be subtle. However, it can progress to septic shock more quickly than in immunocompetent patients. Early prediction of complications and recognition of risk factors can improve outcome. Systemic inflammation is characterized by insulin resistance, dyslipidemia and adipocyte dysfunction. However, their importance in predicting complications and outcome of febrile neutropenia is not entirely known.Aims: To determine changes in HOMA-IR, total cholesterol, triglycerides, HDL - cholesterol, LDL - cholesterol, apolipoprotein A-I, lipoprotein (a) and adiponectin in patients before chemotherapy and during febrile neutropenia. To compare HOMA-IR, total cholesterol, triglycerides, HDL - cholesterol, LDL - cholesterol, apolipoprotein A-I, lipoprotein (a) and adiponectin in patients before chemotherapy and the obese. To compare HOMA-IR, total cholesterol, triglycerides, HDL - cholesterol, LDL - cholesterol, apolipoprotein A-I, lipoprotein (a) and adiponectin in patients during febrile neutropenia and the obese. To determine whether HOMA-IR, total cholesterol, triglycerides, HDL - cholesterol, LDL - cholesterol, apolipoprotein A-I, lipoprotein (a) and adiponectin in febrile neutropenia are in correlation with the severity of the infection, appearance of complications and outcome. Materials and methods: The study was conducted at the Clinic for hematology and Clinic for endocrinology, diabetes, and metabolic disorders. 60 patients who fulfilled the inclusion criteria were included in the study. 30 patients had acute leukemia, and 30 were obese. Clinical and laboratory examination to assess insulin sensitivity, metabolic disorders and adiponectin was done before chemotherapy and during febrile neutropenia. Patients were followed up until the end of the first hospitalization. Data were analyzed with Statistica software and presented in tables and graphs. Statistical significance was set at p<0.05. Results: During febrile neutropenia, patients with acute leukemia developed insulin resistance (t = - 2.43, p = 0.021), alongside significant decline of total cholesterol (t = 3.59, p = 0.0012), LDL – cholesterol (t = 3.56, p = 0.0013) and apoA – I (t = 2.27, p = 0.03). In acute inflammation, metabolic changes in patients with acute leukemia resembled those in the obese with insulin resistance. HOMA-IR values were in positive correlation with fibrinogen (r = 0.59, p < 0.05) whereas apoA-I was in negative correlation to CRP (r = - 0.37, p < 0.05). Patients with higher body mass index and waist circumference had better course and outcome of febrile neutropenia (r = - 0.47, p < 0.05 vs. r = - 0.40, p < 0.05). Patients with lower insulin levels and HDL - cholesterol prior to chemotherapy had a significantly better course of febrile neutropenia (t = -2.38, p = 0.024 vs. t = - 2.87, p = 0.007). Other parameters of insulin sensitivity, metabolic status, and adiponectin did not influence the course and outcome of inflammation significantly. Normal body weight, duration of febrile neutropenia for longer than 7 days, lower MASCC risk index, higher CRP and adiponectin, low Lp(a) in febrile neutropenia and a complicated course od febrile neutropenia were predictors of a worse outcome. Conclusion: Besides known hematological risk factors for complications in febrile neutropenia, anthropometric characteristics, fat mass distribution and disfunction, insulin resistance and metabolic parameters are useful predictors of the course and outcome of febrile neutropenia.
2
Urbonas, Vincas. "Biomarkers of bacteremia and sepsis in pediatric oncology patients with febrile neutropenia." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2013. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2013~D_20131115_080913-61678.
Full textAbstract:
This study was designed to evaluate the response of innate immunity to acute bacterial inflammation in terms of cytokines and other biomolecules concentration changes in the blood of investigated childhood oncology patients during the beginning of febrile neutropenia (FN) episode and to assess the relevance of these biomarkers for sepsis/bacteremia evaluation. This study was performed at Vilnius University Children Hospital and State Research Institute Centre for Innovative Medicine from 2009 to 2011. Serum samples were collected during 82 fever episodes in a total of 53 oncology patients. The study population consisted of pediatric oncology patients admitted to the hospital with the diagnosis of neutropenia and fever. According to microbiological and clinical findings, patients with episodes of FN were classified into 2 groups: 1) fever of unknown origin (FUO) group – patients with negative blood culture, absence of clinical signs of sepsis and clinically or microbiologically documented local infection, 2) septic/bacteremia (SB) group – patients with positive blood culture (documented Gram-positive or Gram-negative bacteremia) and/or clinically documented sepsis. We measured the levels of cytokines (IL-6, IL-8, IL-10), their receptors (sIL-2R) and other biomarkers (PCT, CRP, sHLA-G) for three consecutive days. We showed that on day 1 the most accurate biomarkers for bacteremia/sepsis discrimination were cytokines (IL-6, IL-10, IL-8), on day 2 – IL-8 and PCT. On day 1 the... [to full text]Viena iš pagrindinių taikomos šiuolaikinės intensyvios chemoterapijos komplikacijų yra organizmo imuninės sistemos slopinimas ir su tuo susijusi neutropenija, kuri savo ruožtu sąlygoja padidėjusią riziką susirgti bakterinės kilmės infekcinėmis ligomis. Šio darbo tikslas buvo įvertinti ūmaus bakterinio uždegimo bei sepsio patogenezėje dalyvaujančių citokinų (IL-6, IL-8, IL-10), citokinų receptorių (sIL-2R), ūmios fazės baltymų bei kitų imuninio atsako komponentų (CRB, PCT, sHLA-G) tinkamumą bakterinio proceso ankstyvai diagnostikai tarp pacientų su febrline neutropenija (FN), šių biožymenų tinkamumą ir pritaikomumą kasdienėje klinikinėje praktikoje. Tiriamoji medžiaga surinkta 2009–2011 m. Vilniaus universiteto Vaikų ligoninės Onkohematologijos skyriuje. Į tyrimą buvo įtraukta 53 onkohematologinėmis ligomis sergantys vaikai su FN, kurie gydymo eigoje turėjo 82 karščiavimo epizodus. Nuo pirmos karščiavimo dienos tris dienas iš eilės buvo imami kraujo mėginiai bei nustatomos citokinų (IL-6, IL-8, IL-10), CRB, PCT, sHLA-G ir sIL-2R koncentracijos. Remiantis klinikinių bei mikrobiologinių tyrimų duomenimis, FN epizodai buvo suskirstyti į dvi grupes – neaiškios kilmės karščiavimo (NKK), į kurią buvo įtraukti pacientai be sepsio požymių bei su neigiamais mikrobiologiniais pasėliais ir bakteriemijos/sepsio (BS). BS grupę sudarė pacientai su teigiamais mikrobiologiniais pasėliais ir(ar) kliniškai diagnozuotu sepsiu. Mūsų atlikto tyrimo rezultatais bakteriemijos/sepsio vertinimui FN... [toliau žr. visą tekstą]
3
Urbonas, Vincas. "Vaikų, sergančių navikinėmis ligomis, bakteriemijos bei sepsio biožymenys febrilinės neutropenijos epizodo metu." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2013. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2013~D_20131115_080926-38717.
Full textAbstract:
Viena iš pagrindinių taikomos šiuolaikinės intensyvios chemoterapijos komplikacijų yra organizmo imuninės sistemos slopinimas ir su tuo susijusi neutropenija, kuri savo ruožtu sąlygoja padidėjusią riziką susirgti bakterinės kilmės infekcinėmis ligomis. Šio darbo tikslas buvo įvertinti ūmaus bakterinio uždegimo bei sepsio patogenezėje dalyvaujančių citokinų (IL-6, IL-8, IL-10), citokinų receptorių (sIL-2R), ūmios fazės baltymų bei kitų imuninio atsako komponentų (CRB, PCT, sHLA-G) tinkamumą bakterinio proceso ankstyvai diagnostikai tarp pacientų su febrline neutropenija (FN), šių biožymenų tinkamumą ir pritaikomumą kasdienėje klinikinėje praktikoje. Tiriamoji medžiaga surinkta 2009–2011 m. Vilniaus universiteto Vaikų ligoninės Onkohematologijos skyriuje. Į tyrimą buvo įtraukta 53 onkohematologinėmis ligomis sergantys vaikai su FN, kurie gydymo eigoje turėjo 82 karščiavimo epizodus. Nuo pirmos karščiavimo dienos tris dienas iš eilės buvo imami kraujo mėginiai bei nustatomos citokinų (IL-6, IL-8, IL-10), CRB, PCT, sHLA-G ir sIL-2R koncentracijos. Remiantis klinikinių bei mikrobiologinių tyrimų duomenimis, FN epizodai buvo suskirstyti į dvi grupes – neaiškios kilmės karščiavimo (NKK), į kurią buvo įtraukti pacientai be sepsio požymių bei su neigiamais mikrobiologiniais pasėliais ir bakteriemijos/sepsio (BS). BS grupę sudarė pacientai su teigiamais mikrobiologiniais pasėliais ir(ar) kliniškai diagnozuotu sepsiu. Mūsų atlikto tyrimo rezultatais bakteriemijos/sepsio vertinimui FN... [toliau žr. visą tekstą]This study was designed to evaluate the response of innate immunity to acute bacterial inflammation in terms of cytokines and other biomolecules concentration changes in the blood of investigated childhood oncology patients during the beginning of febrile neutropenia (FN) episode and to assess the relevance of these biomarkers for sepsis/bacteremia evaluation. This study was performed at Vilnius University Children Hospital and State Research Institute Centre for Innovative Medicine from 2009 to 2011. Serum samples were collected during 82 fever episodes in a total of 53 oncology patients. The study population consisted of pediatric oncology patients admitted to the hospital with the diagnosis of neutropenia and fever. According to microbiological and clinical findings, patients with episodes of FN were classified into 2 groups: 1) fever of unknown origin (FUO) group – patients with negative blood culture, absence of clinical signs of sepsis and clinically or microbiologically documented local infection, 2) septic/bacteremia (SB) group – patients with positive blood culture (documented Gram-positive or Gram-negative bacteremia) and/or clinically documented sepsis. We measured the levels of cytokines (IL-6, IL-8, IL-10), their receptors (sIL-2R) and other biomarkers (PCT, CRP, sHLA-G) for three consecutive days. We showed that on day 1 the most accurate biomarkers for bacteremia/sepsis discrimination were cytokines (IL-6, IL-10, IL-8), on day 2 – IL-8 and PCT. On day 1 the... [to full text]
4
Bellesso, Marcelo. "Tratamento ambulatorial da neutropenia febril." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-02062009-093637/.
Full textAbstract:
INTRODUÇÃO: A neutropenia febril (NF) é uma complicação freqüente e potencialmente fatal no manejo do paciente onco-hematológico. Estudos recentes demonstram que a NF consiste em um grupo heterogêneo de pacientes com riscos variados. Nosso objetivo foi avaliar a taxa de falência ao tratamento de primeira linha, taxa de internação e óbito. Além disso, estudamos as variáveis clínico-laboratoriais em relação aos desfechos, a validação do índice Multinational Association for Supportive Care of Cancer (MASCC) modificado e a taxa de positividade de hemocultura e urocultura, como também o perfil de sensibilidade ao cefepima. CASUÍSTICA E METODOLOGIA: Estudo retrospectivo unicêntrico. Os dados foram obtidos através dos prontuários do Hospital-Dia no período de Julho de 2001 a Junho de 2006. Foram avaliados eventos com NF tratados com cefepima 2g (2x/dia), associado ou não, a teicoplamina 400mg/dia. RESULTADOS: Em 128 pacientes, estudamos 178 eventos de NF. A taxa de falência ao tratamento de primeira linha foi de 36,5%, taxa de internação 20,7% e óbito em 6,2% entre os eventos de NF. Na análise multivariada do estudo das categorias clínico-laboratoriais e dos desfechos encontramos como dados significantes em relação ao risco da falência ao tratamento de primeira linha: Idade < 60 anos (OR: 2,11 IC95%: 1,71-2,51, p = 0,004) e creatinina sérica > 1,2mg/dL (OR: 7,19, IC95%: 1,81 30,71 p= 0,005). Os dados significantes para o risco de internação foram: Ausência do diagnóstico de Linfoma não - Hodgkin (OR: 2,42 IC95%: 2,04 2,8, p= 0,011) Tabagismo (OR: 3,14, IC95% 1,14 8,66, p=0,027) e creatinina sérica > 1,2mg/dL (OR: 7,97, IC95% 21,19 - 28,95, p=0,002). Em relação ao óbito, o único dado de risco significante foi a saturação de oxigênio < 95% (OR: 5,8, IC95% 1,50 - 22,56, p = 0,011). Em relação ao índice MASCC modificado e seu impacto sobre os desfechos obtivemos os seguintes resultados: Falência do tratamento de primeira linha e (baixo risco versus alto risco): 35,2% x 53,8%, p=0,232; Internação (baixo risco versus alto risco): 18,2% x 53,8%, p = 0,006; óbito (baixo risco versus alto risco): 4,3% x 30,8%, p=0,004. As taxas de hemocultura e urocultura positivas foram respectivamente: 13% e 8%. O agente isolado mais freqüente nos dois exames foi Eschericia coli. Em relação ao perfil de sensibilidade dos agentes isolados e testados, 100% foram sensíveis ao cefepima. CONCLUSÕES: Os eventos de NF em tratamento ambulatorial apresentaram taxas satisfatórias em relação aos desfechos. Os dados sugerem que os riscos como: Ausência de Linfoma não - Hodgkin, tabagismo, creatinina sérica > 1,2mg/dL e oximetria de pulso < 95% merecem ser considerados como fatores de riscos para desfechos indesejáveis. O índice MASCC modificado mostrou-se eficaz para classificar os eventos classificados como alto risco na nossa população. Em relação aos agentes isolados e testados, 100% são sensíveis ao antibiótico de primeira linha cefepima.BACKGROUND AND OBJECTIVES: Febrile Neutropenia (FN) is a frequent adverse event and potentially lethal in patients with haematologic malignancies. Nowadays, FN represents a heterogeneous group with different risk for serious complications and death. We studied the first line antibiotic failure, hospitalization rate and death. In addition, it was compared clinical and laboratory data with outcomes, validation of the usefulness of Modified Multinational Association for Supportive Care of Cancer (MASCC) and blood culture and urine culture rate identification. DESIGN AND METHODS: We elaborated a retrospective study. It was evaluated patients with haematologic malignancies who were treated with Cefepime 2g intravenous (IV) twice a day, with or without Teicoplanin 400mg (IV) once a day. RESULTS: Of the 178 FN events, it was observed: first line antibiotic failure 36,5%, hospitalization rate 20,7% and deaths 6,2%. In multivariate analyses, it was evidenced with risk to first line antibiotic failure: Age < 60 years (OR: 2,11, CI95%: 1,71-2,51, p =0,004), serum creatinine > 1,2mg/mL (OR: 7,19, CI95%: 1,81 30,71 p= 0,005). In hospitalization the risks were: Without diagnosis of Non- Hodgkin Lymphoma (OR: 2,42, CI95%: 2,04 2,8, p= 0,011), smoking (OR: 3,14, CI95% 1,14 8,66, p=0,027), serum creatinine > 1,2mg/dL (OR: 7,97, CI95%21,19- 28,95, p=0,002). Relating to death, the risk was transcutaneous oximetry < 95% (OR: 5.8, CI95%: 1.50 22.56, p = 0.011). Analyzing MASCC index, 165 events were classified as low-risk and 13 as high-risk. Outpatient treatment failures were reported in connection with 7 (53.8%) high-risk episodes and 30 (18.2%) low-risk, p=0.006. In addition, death in 7 (4.2%) low-risk and 4 (30.8%) high-risk events, p=0.004. Microbiological infection documented was identified in 13% and 8% in blood cultures and urine cultures, respectively. The most common agent isolated was E. coli and 100% were sensitive to cefepime. INTERPRETATIONS AND CONCLUSIONS: The outpatient treatment with intravenous antibiotic was satisfactory. The risks: Haematologic malignancies other than Non-Hodgkin Lymphoma, smoking, serum creatinine elevated and oximetry < 95% should be considered in FN evaluation. It was validated MASCC index in the Brazilian population. Relating to microbiological agents studied 100% were not resistant for cefepime.
5
Rosa, Regis Goulart. "Desfechos clínicos em neutropenia febril." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/119418.
Full textAbstract:
Neutropenia febril (NF) constitui complicação frequente do tratamento quimioterápico do câncer e está associada a altas taxas de morbimortalidade. O reconhecimento dos principais fatores associados ao desenvolvimento de desfechos clínicos desfavoráveis na NF é fundamental, uma vez que estes podem ser utilizados como marcadores prognósticos ou alvos terapêuticos. Este estudo objetiva determinar os principais fatores associados com mortalidade, tempo de hospitalização, incidência de bacteremia por patógenos multirresistentes e incidência de choque séptico no início da febre em pacientes hospitalizados com NF secundária à quimioterapia citotóxica para o câncer. Na presente coorte prospectiva composta por 305 episódios consecutivos de NF (em 169 pacientes com câncer) realizada em um hospital terciário no período de outubro de 2009 a agosto de 2011, as seguintes questões de pesquisa foram avaliadas: impacto do tempo de início da antibioticoterapia na mortalidade em 28 dias; fatores relacionados com tempo de hospitalização; impacto dos fatores microbiológicos da bacteremia no desenvolvimento de choque séptico no início do episódio de NF; fatores de risco para bacteremia por patógenos multirresistentes; impacto da bacteremia por Staphylococcus coagulase-negativo na mortalidade em 28 dias. Em 5 publicações distintas, os seguintes resultados foram notados: o atraso do início da antibioticoterapia está associado a maiores taxas de mortalidade em 28 dias; neoplasia hematológica, regimes quimioterápicos de altas doses, duração da neutropenia e bacteremia por Gram-negativos multirresistentes estão associados com períodos prolongados de internação por NF; infecção de corrente sanguínea polimicrobiana, bacteremia por Escherichia coli e bacteremia por Streptococcus viridans estão associados a choque séptico no início do episódio de NF; idade avançada, duração da neutropenia e presença de cateter venoso central estão associados com bacteremia por patógenos multirresistentes; bacteremia por Staphylococcus coagulase-negativo está associada a menores taxas de mortalidade em 28 dias quando comparado à bacteremia por outros patógenos.Febrile neutropenia (FN) is a common complication of cancer chemotherapy and is associated with high morbidity and mortality rates. Recognition of the main factors associated with the development of adverse clinical outcomes in FN is crucial, given that these factors can be used as prognostic markers or therapeutic targets. This study aims to determine the main factors associated with mortality, length of hospital stay, incidence of bacteremia by multidrug-resistant pathogens and incidence of septic shock at the onset of fever in hospitalized patients with FN secondary to cancer cytotoxic chemotherapy. In the present prospective cohort of 305 FN episodes (in 169 cancer patients) conducted at a tertiary hospital from October 2009 to August 2011, the following research questions were evaluated: impact of time to antibiotic administration on 28-day mortality; factors associated with length of hospital stay; impact of microbiological factors of bacteremia on the development of septic shock at the onset of FN; risk factors for bacteremia by multidrug-resistant pathogens; impact of coagulasenegative Staphylococcus bacteremia on 28-day mortality. In 5 distinct publications, the following results were noted: delay of antibiotic administration is associated with higher 28-day mortality rates; hematologic malignancy, high-dose chemotherapy regimens, duration of neutropenia and bacteremia by multidrug-resistant Gram-negative bacteria are associated with prolonged length of hospital stay; polymicrobial bloodstream infection, bacteremia by Escherichia coli, and bacteremia by viridans sreptococci are associated with septic shock at the onset of FN; advanced age, duration of neutropenia and presence of indwelling central venous catheters are associated with bacteremia by multidrug-resistant pathogens; coagulase-negative Staphylococcus bacteremia is associated with lower 28-day mortality rates compared with bacteremia by other pathogens.
6
Bossaer, John B., and David Cluck. "Home Health Care of Patients With Febrile Neutropenia." Digital Commons @ East Tennessee State University, 2013. https://dc.etsu.edu/etsu-works/2319.
Full textAbstract:
Febrile neutropenia is a potentially life-threatening oncologic emergency characterized by a dangerously low neutrophil count that places the patient at great risk. In these patients, fever may be the only sign of infection, which requires prompt treatment. With the increasing focus in shifting health care from inpatient centers to outpatient arenas, home health care clinicians will likely have an increased role in the care of neutropenic fever patients in the future. The article describes both the pharmacologic treatment and nonpharmacologic support required of these patients with particular attention to treatment that may be required in the patient?s home.
7
Barbosa, Gustavo Göhringer de Almeida. "Expressão do CD64 como preditor de cultural positivo em crianças com neutropenia febril." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2014. http://hdl.handle.net/10183/104077.
Full textAbstract:
Introdução: Uma em cada 25 crianças com câncer vai morrer devido a complicações da terapia: trata-se de uma em cada seis mortes. Das complicações do tratamento, uma importante causa de morte continua sendo a infecção. Esta frequentemente apresenta-se como febre com neutropenia, mais conhecido como “neutropenia febril”. O reconhecimento precoce de processos infecciosos em pacientes neutropênicos é dificultado pelo fato destes poderem ter apresentações clínicas variadas e não específicas, aguardando-se o início da febre para se começar um tratamento com antibióticos. O CD64 é um marcador de superfície de neutrófilos, detectável por exame de citometria de fluxo e que é pouco expressado em neutrófilos não sensibilizados. Quando o neutrófilo é exposto a TNF- alfa e outros mediadores inflamatórios, este marcador passa a ser ativado e é mensurado através da expressão do Índice de CD64. Justificativa: O diagnóstico precoce de sepse com hemocultura positiva em crianças neutropênicas febris é de suma importância. Os testes laboratoriais disponíveis nos ajudam pouco no momento da chegada deste paciente ao hospital. O diagnóstico mais precoce de uma infecção bacteriana nestes pacientes possibilita um melhor manejo da antibióticoterapia e, consequentemente, uma melhora na sobrevida. Objetivos: O objetivo deste trabalho foi de avaliar a existência de relação entre o valor do índice de CD64 no primeiro dia de neutropenia febril com a positividade da hemocultura. A correlação com outros parâmetros, como número de leucócitos, PCR e VSG também foi avaliada. Metodologia: Este foi um estudo do tipo casos e controles, prospectivo, diagnóstico, com 64 episódios de neutropenia, sendo o grupo de casos definido como aquele com hemoculturas positivas e o controle com hemoculturas negativas. O grupo de casos contou com 14 episódios e o grupo de controle com 50. Por se tratar de uma variável não-paramétrica, utilizamos o teste de Mann-Whitney para relacionar o índice de CD64 com os resultados da hemocultura em cada grupo e com as demais variáveis. Para avaliar a capacidade de prever o resultado de uma hemocultura com o índice de CD64 e também avaliarmos suas medidas de eficácia, utilizamos curva ROC (Receiver Operating Characteristic) Resultados: O grupo de casos contou com 14 pacientes. A mediana do índice de CD64 no grupo de casos foi de 2,1 (±3,9) e para o grupo controles foi de 1,76(±5,02). Os testes de Mann-Whitney não foram capazes de evidenciar relação entre o valor do índice de CD64 e a positividade das hemoculturas. O índice de CD64 também não se mostrou correlacionado com a positividade do PCR. A curva ROC não evidenciou que o Índice de CD64 foi capaz de prever a positividade de uma hemocultura. Com relação às medidas de eficácia, tivemos: Sensibilidade de 64,3%, especificidade de 42% com valor preditivo positivo de 23,7% e valor preditivo negativo de 80%. O valor linear do PCR não apresentou diferença estatísticamente significativa entre os grupos das hemoculturas. Para o PCR as medidas de eficácia do exame foram: Sensibilidade de 71,4%, especificidade de 32% com valor preditivo positivo de 22,7% e valor preditivo negativo de 80%. Conclusão: Em desacordo com a literatura, o índice de CD64 se mostrou inadequado para prever a positividade de hemocultura nesta população específica de pacientes com neutropenia febril. O valor linear da PCR também não foi capaz de prever a positividade dos culturais nos neutropênicos febris. Deste modo, ambos os exames não são adequados para prever positividade de culturais em crianças neutropências febris.Introduction : One in every 25 children with cancer will die from therapy complications: it means one in six deaths. Between these patients, a major cause of death remains infection. This condition often presents as fever with neutropenia, better known as “febrile neutropenia." Early recognition of infectious processes in neutropenic patients is hampered by the fact that these may have dissimilar and non-specific clinical presentations, pending the onset of fever to start treatment with antibiotics. The CD64 is a neutrophil surface marker, detectable by flow cytometry tests, and are not expressed in non-sensitized neutrophils. When the neutrophil is exposed to TNF-alpha and other inflammatory mediators, it is activated and is measured via the CD64 index. Rationale: The early diagnosis of sepsis with positive blood culture in febrile neutropenic children is of utmost importance. Laboratory tests available help us little in the moment this patient arrives at the hospital. The early diagnosis of a bacterial infection in these patients allows a better management of antibiotic therapy and, consequently, an improvement in survival. Objectives: The main objective of this paper is to evaluate the existence of a relationship between the index value of CD64 on the first day of febrile neutropenia with positive blood culture. The correlation with other parameters such as leukocyte count, CRP and ESR was also evaluated. Methodology: This is a cases-control, prospective, diagnosis study that included 64 episodes of neutropenia. The cases group(n=14) was defined by those with positive blood cultures and the control(n=50) one with negative blood cultures. Because it is a non - parametric variable, we used the Mann-Whitney correlation test to relate the index of CD64 with the result of blood culture in each group and with the other variables. A ROC (Receiver Operating Characteristic) curve was used to assess the competence of the CD64 index to predict the outcome of blood culture. The median rate of CD64 in the case group was 2,1 (±3,9) and controls for the group was 1,76(±5,02). The Mann-Whitney tests were not able to show the relationship between the value of CD64 index and the results of blood cultures. The CD64 index was also not correlated with the positivity of CRP. The ROC curve did not show that the CD64 index was able to predict the positivity of blood culture. Regarding efficacy measurmements, sensibility was 64,3%, specificity 42%, positive predictive value 23,7% and negative predictive value 80%. The linear value of CRP showed no statistically significant difference between the groups of blood cultures. For CRP, the efficacy measurements were sensibility 71,4%, specificity 32%, positive predictive value 22,7% and negative predictive value 80%. Conclusion: CD64 index was not suitable to predict the positivity of blood cultures in this specific population of patients with febrile neutropenia. Also the linear values of CRP showed no statistically significant difference between the blood culture groups. Therefore, both exams should not be used in order to predict positivity of cultural in neutropenic febrile childen.
8
Sánchez, Lombardi Ignacio Ándres. "Monitorización individualizada de amikacina en pacientes con neutropenia febril." Tesis, Universidad de Chile, 2018. http://repositorio.uchile.cl/handle/2250/168510.
Full textAbstract:
Grado de magíster en farmacologíaIntroducción: La neutropenia febril es la reacción adversa (RAM) más severa de los agentes quimioterapéuticos y que predispone a los pacientes con cáncer a infecciones graves1, siendo esencial la administración rápida de antimicrobianos.7-8 Las recomendaciones nacionales e internacionales incluyen el uso de aminoglucósidos.1,5-10 Sin embargo, para asegurar un correcto resultado, esta terapia antibiótica requiere una adecuada monitorización. En esta investigación, se pretende establecer el tiempo más adecuado de monitorización de amikacina en pacientes con neutropenia febril, para asegurar un régimen posológico seguro y eficaz que contribuya al manejo y recuperación de estos pacientes. Objetivo: Determinar el esquema más adecuado para monitorizar amikacina en pacientes con neoplasias y otras patologías hematológicas, que cursan con neutropenia febril en un hospital de alta complejidad, que es centro de referencia de pacientes hematoncológicos. Metodología: Se realizó un estudio prospectivo aleatorizado doble ciego, que comparó dos estrategias de monitoreo plasmático: uno mediante la toma de nivel en valle, contra uno a las 12 horas posterior al término de la infusión. Ambos grupos se caracterizaron y analizaron según sus parámetros farmacocinéticos y el cumplimiento de los parámetros Farmacocinético/Farmacodinámico (FC/FD), evaluándose además la correlación e influencia de ciertos factores como el clearence de amikacina y creatinina. Para el cálculo del régimen posológico de amikacina como indicación médica, se utilizó un modelo farmacocinético teórico del programa TDMS2000®. Resultados: Se incluyó un total de 42 pacientes, de los cuales 21 comprendieron a los que se les monitorizó en valle. El 81,0% de los pacientes que se les monitorizó en valle tuvieron niveles < 1, de los cuales 38,1% fueron en cero, en el caso de la monitorización a las 12 horas sólo en 9,5% tuvieron niveles < 1. Al individualizar las dosis hubo un aumento de 15 a 19 mg/Kg, siendo así el 85,7% de los pacientes cumplieron el Cmáx/CIM ≥ 8 en ambos grupos. Sin embargo, en el caso del ABC/CIM > 70, sólo 14,3% de los pacientes con niveles valle cumplieron con el parámetro objetivo versus aquellos que se les midió niveles a las 12 horas que fue un 42,3%, presentando diferencia estadística significativa. En el caso de la seguridad ningún paciente presentó disfunción renal en ambos grupos, objetivándose en 21 días de tratamiento. Por otra parte, se encontró una correlación directa entre el clearence de creatinina y el de amikacina. Conclusión: Finalmente, se puede concluir que la monitorización de amikacina a las 12 horas cuando se utiliza un programa farmacocinético con modelación bayesiana, es un método más adecuado y efectivo que la monitorización valle en el cumplimiento FC/FD. La monitorización farmacocinética de amikacina es un método seguro en la prevención de nefrotoxicidad en tratamientos prolongados.
9
Perazzoli, Camila. "Estudo das afecções abdominais e anorretais em pacientes hematológicos neutropênicos febris. Análise da casuística, fatores de risco para mortalidade e proposta de escore de gravidade." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/17/17137/tde-08012019-155704/.
Full textAbstract:
Introdução. Pacientes neutropênicos febris, particularmente os portadores de doenças hematológicas, podem ter como causa de sua descompensação clínica afecções abdominais e anorretais. O acompanhamento do quadro infeccioso é motivo de angústia para o cirurgião coloretal, pois a literatura sobre o tema é restrita e quadros oligosintomáticos eventualmente evoluem para óbito em curto espaço de tempo. Objetivos. Descrever, estratificar e comparar com a literatura a casuística de pacientes hematológicos neutropênicos febris com foco abdominal ou anorretal identificado. Estudar o risco absoluto e relativo de mortalidade de algumas variáveis associadas com a condição. Propor um escore de gravidade das afecções abdominais e anorretais em pacientes hematológicos neutropênicos febris. Materiais e Métodos. Trata-se de um estudo a partir da análise retrospectiva de 897 prontuários médicos de pacientes internados para as equipes de Hematologia e Transplante Células Tronco Hematopoéticas, no Hospital de Clínicas da Universidade de São Paulo, Ribeirão Preto-SP, entre os anos de 2008-2013. Foram elegíveis para o estudo 74 episódios de neutropenia febril com foco infeccioso abdominal ou anorretal, ocorridos em 69 pacientes. Após coletadas as características a respeito da amostra, foram estratificados os dados, comparados com a literatura sobre o tema, realizados os cálculos de medidas de efeito e análise estatística. Por fim, considerando os resultados obtidos, a experiência clínica dos autores e critérios de plausibilidade biológica comum, foram selecionados cinco aspectos como sendo os principais preditores de mortalidade hospitalar em pacientes hematológicos neutropênicos febris, com afecção abdominal ou anorretal. Resultados. O escore proposto demonstrou possuir mortalidade crescente conforme o quadro se agrava e a pontuação se eleva (teste exato de Fischer: 0,001). Ao considerar o modelo logístico de probabilidade de óbito por nível do escore, o valor encontrado AUC foi de 0,82 (0,72-0,925) e o valor de Estatística de Hosmer-Lemeshow de 2,3, com p=0,806. Discussao. Os escores contribuem na prática clínica diária para a tomada objetiva de decisões. De forma semelhante ao escore APACHE e seus refinamentos, o sistema prognóstico proposto possui variáveis de fácil acesso e traduz de maneira satisfatória o comportamento e a confiabilidade dos resultados obtidos, através da AUC>0,8 e estatística de Hosmer-Lemeshow com p> 0,05. Conclusão. O sistema de escore proposto permite predizer a chance de óbito durante a internação em pacientes neutropênicos febris com afeccção abdominal ou anorretal. Novos estudos sobre o tema são necessários e o escore proposto necessita e deve ser validado em uma amostra maior e distinta de pacientes.Introduction. Febrile neutropenic patients, particularly those with haematological diseases, may have abdominal and anorectal conditions as a cause of their clinical decompensation. The follow-up of the infectious condition is a cause of distress for the colorectal surgeon, because the literature on the subject is restricted and oligosymptomatic conditions can lead to death within a short period of time.Goals. To describe, stratify and compare with the literature the casuistry of febrile neutropenic haematological patients with abdominal or anorectal focus identified. To study the absolute and relative risk of mortality of some variables associated with the condition. To propose a severity score of abdominal and anorectal conditions in neutropenic hematologic febrile patients. Materials and Methods. This is a study based on the analysis of 897 medical records of inpatients for hematology and hematopoietic stem cell transplantation (HSCT) teams at the Hospital de Clínicas of the University of São Paulo, Ribeirão Preto-SP, between the years of 2008-2013. A total of 74 episodes of febrile neutropenia with infectious abdominal or anorectal conditions occurred in 69 patients. After collecting the characteristics regarding the sample, the data were stratified, compared to the literature on the subject, the calculations of effect measures and statistical analysis were performed. Finally, considering the results obtained, the author\'s clinical experience and criteria of common biological plausibility, five aspects were selected as the main predictors of hospital mortality in febrile neutropenic haematological patients with abdominal or anorectal disease. Results. The proposed score showed an increasing mortality rate as the condition worsens and the score rises (Fischer\'s exact test: 0.001). When considering the logistic model of death probability by level of the score, the AUC value found was 0.82 (0.72-0.925) and the Hosmer-Lemeshow statistic value was 2.3, with p = 0.806. Discussion. The scores contribute to daily clinical practice for objective decision making. Similar to the APACHE score and its refinements, the proposed prognostic system has easily accessible variables and satisfactorily translates the behavior and reliability of the results obtained through AUC> 0.8 and Hormer-Lemeshow statistics with p> 0,05. Conclusion. The proposed score system allows predicting the chance of death during hospitalization in febrile neutropenic patients with abdominal or anorectal disease. New studies on the subject are necessary and the proposed score needs and must be validated in a larger and different sample of patients.
10
Graham, Emily Nicole. "Optimizing Care for Oncologic and Hematologic Patients with Febrile Neutropenia." The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1483522367955844.
Full textBooks on the topic "Febrilna neutropenija"
2
Klastersky, Jean A., ed. Febrile Neutropenia. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0.
Full text
3
Klastersky, Jean A. Febrile Neutropenia. Tarporley: Springer Healthcare Ltd., 2014. http://dx.doi.org/10.1007/978-1-907673-70-2.
Full text
6
Kenneth V I Rolston (Editor) and Edward B. Rubenstein (Editor), eds. Textbook of Febrile Neutropenia. Informa Healthcare, 2001.
Find full text
7
I, Rolston Kenneth V., and Rubenstein Edward B, eds. Textbook of febrile neutropenia. London: Martin Dunitz, 2001.
Find full text
8
Textbook of Febrile Neutropenia. Abingdon, UK: Taylor & Francis, 1988. http://dx.doi.org/10.4324/9780203215272.
Full text
9
Champigneulle, Benoit, and Frédéric Pène. Pathophysiology and management of neutropenia in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0274.
Full textAbstract:
Neutropenia is defined by an absolute neutrophil count <500 per mm3. Chemotherapy-induced myelosuppression represents the main mechanism accounting for neutropenia, although various bone marrow disorders might also result in impaired granulopoiesis. Neutropenia, especially when profound and prolonged, is a major risk factor for severe bacterial and fungal infections. Early initiation of empirical broad-spectrum antibiotic therapy represents the cornerstone of the treatment of febrile neutropenia. A number of infected neutropenic patients may exhibit organ failures, such as acute respiratory failures and/or severe sepsis requiring intensive care unit (ICU) admission. This chapter discusses the particularities in the management of neutropenic patients in the ICU, including outcome and criteria for ICU admission, management of antimicrobials with respect to the current epidemiological trends, and other measures specific to this subgroup of patients.
10
Ison, Michael G. Upper Respiratory Symptoms During Febrile Neutropenia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0012.
Full textAbstract:
These case studies illustrate infections encountered in hospitals among patients with compromised immune systems. As a result of immunocompromise, the patients are vulnerable to common and uncommon infections. These cases are carefully chosen to reflect the most frequently encountered infections in the patient population, with an emphasis on illustrations and lucid presentations to explain state-of-the-art approaches in diagnosis and treatment. Common and uncommon presentations of infections are presented while the rare ones are not emphasized. The cases are written and edited by clinicians and experts in the field. Each of these cases highlights the immune dysfunction that uniquely predisposed the patient to the specific infection, and the cases deal with infections in the cancer patient, infections in the solid organ transplant recipient, infections in the stem cell recipient, infections in patients receiving immunosuppressive drugs, and infections in patients with immunocompromise that is caused by miscellaneous conditions.
Book chapters on the topic "Febrilna neutropenija"
1
Tattersall, M. H. N. "High-Dose Chemotherapy: Safer and Better?" In Febrile Neutropenia, 1–5. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_1.
Full text
2
Rolston, K. V. I., I. Raad, E. Whimbey, and G. P. Bodey. "The Changing Spectrum of Bacterial Infections in Febrile Neutropenic Patients." In Febrile Neutropenia, 53–56. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_10.
Full text
3
Pierard, D., A. De Meyer, and S. Lauwers. "Susceptibility of Streptococci Isolated from Blood of Neutropenic Patients to 11 Antibiotics." In Febrile Neutropenia, 57–58. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_11.
Full text
4
Moreillon, P. "Emerging Antibiotic Resistance in Bacterial Pathogens." In Febrile Neutropenia, 59–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_12.
Full text
5
Breen, J., R. Ramphal, A. Cometta, B. Conetta, and C. Nicaise. "Cefepime versus Ceftazidime as Empiric Therapy of Febrile Episodes in Neutropenic Patients." In Febrile Neutropenia, 63–74. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_13.
Full text
6
Mustafa, M. M. "Cefepime versus Ceftazidime in the Empiric Treatment of Febrile Neutropenic Children with Malignancy." In Febrile Neutropenia, 75–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_14.
Full text
7
Bosly, A., M. Aoun, M. Boogaerts, R. Schots, and V. De Pril. "Cefepime-Vancomycin versus Ceftazidime-Vancomycin as Empiric Therapy in Febrile Neutropenic Patients." In Febrile Neutropenia, 77–78. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_15.
Full text
8
Cometta, A. "Monotherapy with Meropenem versus Combination Therapy with Ceftazidime plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients with Cancer." In Febrile Neutropenia, 79–83. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_16.
Full text
9
Berghmans, T., M. Aoun, and J. A. Klastersky. "Piperacillin plus Tazobactam versus Ceftazidime plus Amikacin in Febrile Neutropenia: A Comparison in Terms of Cost and Efficacy." In Febrile Neutropenia, 85–88. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_17.
Full text
10
Bodey, G. P. "Fungal Infection in Neutropenic Patients: Past Achievements and Future Problems." In Febrile Neutropenia, 89–98. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_18.
Full textConference papers on the topic "Febrilna neutropenija"
1
Lima, Eduarda Rabêlo, Pedro Erbet Belém Filho Morais, Luana Sales de Barros, and Erika Rolim Melo Gurgel. "TRATAMENTO DA NEUTROPENIA FEBRIL NOS PACIENTES EM USO DE QUIMIOTERAPIA: UMA REVISÃO DE LITERATURA." In I Congresso Brasileiro de Hematologia Clínico-laboratorial On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/642.
Full textAbstract:
Introdução: A Neutropenia Febril (NF) pode ser definida através da temperatura oral ≥ 38,3ºC, no momento da aferição ou ≥ 38ºC durante 1 hora, além de uma contagem total de neutrófilos < 500/mm³ ou < 1000/mm³ com tendência de redução em 48 horas. Com o objetivo de estabelecer o tratamento adequado, deve-se realizar a estratificação de risco da NF, com o auxílio do índice de gravidade MASCC (Multinational Association for Supportive Care of Cancer), que pontua até 26 pontos. Objetivo: Revisar e descrever os principais aspectos da neutropenia febril nos pacientes em uso de quimioterapia, assim como as medidas mais eficazes para o seu tratamento. Material e métodos: Foi realizada uma pesquisa na literatura, utilizando as bases de dados PubMed e Scielo. Ao todo, foram revisados 7 artigos científicos, utilizando o descritor “Neutropenia febril em quimioterapia”, publicados entre os anos de 2016 a 2020. Resultados: O tratamento da NF envolve educação quanto a monitorização dos pŕoprios sintomas e tratamento medicamentoso. Em pacientes de baixo risco (MASCC ≥ 21 pontos), hemodinamicamente estáveis e na ausência de infecções de sítio, faz-se uso de antibioticoterapia oral com fluoroquinolona associada à amoxicilina-clavulanato. Em pacientes de alto risco (MASCC < 21 pontos) , faz-se beta-lactâmico antipseudomonas, carbapenêmicos ou piperacilina-tazobactam. Na presença de foco infeccioso, o tratamento deve seguir sua adequação para que haja a cobertura do real agente causador da infecção. Em idosos, é comprovada a relevância do uso de fator de crescimento como profilaxia e deve-se observar presença de uso crônico de glicocorticóides nesses grupos. Em crianças, recentemente tem-se optado pela antibioticoterapia oral nos pacientes de baixo risco, porém deve-se priorizar essa abordagem para pacientes cujas famílias possuam boa adesão medicamentosa. Conclusão: Em suma, a NF é uma emergência oncológica grave decorrente da quimioterapia, potencialmente fatal, desta forma deve ser diagnosticada e tratada o mais precocemente possível.
2
Koster, M. A., and M. Soffler. "The Forgotten Zone: Pseudomembranous Tracheitis as a Cause of Febrile Neutropenia." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5478.
Full text
3
Liew, C., HP Jersmann, PC Robinson, LB To, and PN Reynolds. "Utility of Flexible Bronchoscopy in Severely Immunocompromised Febrile Neutropenic Patients." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2589.
Full text
4
Tsuchida, Shinpei, Hironobu Tsubouchi, Akiko Kitamura, Nobuhiro Matsumoto, and Masamitsu Nakazato. "Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4842.
Full text
5
Armstrong, Sean, and Ireti Farombi. "P380 Time to antibiotics in paediatric febrile neutropenia – experience of a regional unit." In Faculty of Paediatrics of the Royal College of Physicians of Ireland, 9th Europaediatrics Congress, 13–15 June, Dublin, Ireland 2019. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-epa.726.
Full text
6
Yip, HM, N. Seeboruth, and O. Wilkey. "G182(P) Improving care of febrile neutropenia patients: a specialised proforma and risk stratification system." In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference–Online, 25 September 2020–13 November 2020. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2020. http://dx.doi.org/10.1136/archdischild-2020-rcpch.153.
Full text
7
Alkhayyat, S., S. Dent, J. Verreault, A. Robinson, C. Germond, and T. Vandenberg. "Incidence of Febrile Neutropenia with Taxane-Based Systemic Therapy in Women with Early Stage Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-2087.
Full text
8
Younis, T., D. Rayson, and C. Skedgel. "Abstract P6-07-07: Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p6-07-07.
Full text
9
Yee, J., J. Chan, L. Fehrenbacher, D. Fredriks, D. Chen, W. Wong, and D. Colley. "P5-18-05: Incidence of Febrile Neutropenia in Patients Treated with Docetaxel and Cyclophosphamide (TC) for Adjuvant Breast Cancer." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p5-18-05.
Full text
10
Yu, JL, M. Kurin, M. Pasetka, A. Kiss, K. Chan, SS Sridhar, and E. Warner. "Abstract P6-07-06: Primary prophylaxis of febrile neutropenia during adjuvant docetaxel and cyclophosphamide (TC) chemotherapy for breast cancer." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p6-07-06.
Full text